oral ATM kinase inhibitor

Ph. I candidate oncology

biochem-based screen. and BBB penetration opt

J Pharmacol Exp Ther

AstraZeneca, Cambridge, UK

AZD1390 chemical structure oral ATM kinase inhibitor - AstraZeneca, Cambridge, UK

Context. AZD1390 (recently published on by University of Minnesota) is a brain-penetrating Ataxia-Telangiectasia Mutated (ATM) kinase inhibitor under development for brain tumors. The kinase, known for its critical role…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: